Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients

Inclusion Criteria: * Patients with stage 5 chronic kidney disease having been on hemodialysis for at least 90 days * Patients being on stable erythropoiesis-stimulating agent (ESA) dose * Hemoglobin (Hb) 9 - 11 g/dL * Ferritin ≥ 300 ng/mL. * Transferrin saturation (TSAT) ≤ 30% * Hepcidin 5 - 50 nmol/L Exclusion Criteria: * Anemia due to causes other than chronic kidney disease, including hemoglobinopathies, hemolytic anemias, myelodysplasia or malignancy * Blood transfusion within 2 months before administration of study medication. * Iron treatment from 1 week before study medication administration until 1 week after study medication administration. * Previous enrollment in this study * Current or previous (within 60 days before study medication administration) treatment with another investigational drug and/or medical device or participation in another clinical study. * Pregnancy or breast-feeding women of child bearing age. * Known allergy to any component of the PRS-080#022-DP formulation * Positive for hepatitis B surface antigen, anti-hepatitis C virus antibody, or human immunodeficiency virus * Planned surgery during the study period * Unwilling or unable to comply with the protocol, in the judgment of the investigator * Unstable angina, myocardial infarction, percutaneous transluminal coronary angioplasty/stents, apoplexy or coronary artery bypass grafting \<3 months prior screening. * Congestive heart failure: New York Heart Association Class III or IV.